SCHEMBL4181904

SCHEMBL4181904

Fc1ccc2nc(-c3ccc(-c4ccccn4)cc3)[nH]c2c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 7/20 0.80
CBFB Q13951 6/20 0.80
METAP1 P53582 5/20 0.80
CHEK2 O96017 1/20 0.65
SCD O00767 1/20 0.65
CYP11B1 P15538 1/20 0.58
TCF4 P15884 1/20 0.58
CTNNB1 P35222 1/20 0.58
AURKA O14965 1/20 0.57
NPC1 O15118 6/20 0.56
RAB9A P51151 6/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
KDM4E B2RXH2 3/20 0.56
PKM P14618 4/20 0.56
LMNA P02545 3/20 0.56
MAPT P10636 2/20 0.56
KMT2A Q03164 1/20 0.56
HPGD P15428 2/20 0.56
TP53 P04637 1/20 0.56
GAA P10253 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31592929 0.85 CBFB (0.62) METAP2CBFBMETAP1CHEK2SCD
SCHEMBL4812344 0.84 CBFB (0.84) METAP2CBFBMETAP1NPC1RAB9A
SCHEMBL2978439 0.84 CBFB (0.80) METAP2CBFBMETAP1CYP11B1NPC1
SCHEMBL4189664 0.83 CBFB (0.81) METAP2CBFBCHEK2SCDTRPV1
SCHEMBL4184286 0.83 CYP11B1 (0.67) METAP2CBFBMETAP1CHEK2SCD
SCHEMBL28477377 0.82 CYP11B1 (0.70) METAP2CBFBMETAP1CHEK2CYP11B1
SCHEMBL4181882 0.81 METAP2 (0.81) METAP2CBFBMETAP1CHEK2SCD
SCHEMBL27040196 0.81 CBFB (0.58) METAP2CBFBMETAP1CHEK2SCD
SCHEMBL31593030 0.81 CBFB (0.58) METAP2CBFBMETAP1CHEK2SCD
SCHEMBL31592897 0.80 CBFB (0.61) METAP2CBFBMETAP1CHEK2SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US claimed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP claimed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US claimed
EP-1861387-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2007-12-05 EP claimed
WO-2006080821-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2006-08-03 WO claimed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same TRPV1, TRPA1, BDKRB2 METAP2 4226/4885CBFB 1891/4885METAP1 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.